BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H1 2018

Publisher Name :
Date: 31-Jan-2018
No. of pages: 116

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H1 2018

Summary

According to the recently published report 'BDNFNT 3 Growth Factors Receptor - Pipeline Review, H1 2018'; BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) pipeline Target constitutes close to 20 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - BDNF/NT-3 growth factors receptor is a protein encoded by the NTRK2 gene. It is involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity. It acts as receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. It alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2. Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation.

The report 'BDNFNT 3 Growth Factors Receptor - Pipeline Review, H1 2018' outlays comprehensive information on the BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 2, 7 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Cardiovascular, Ear Nose Throat Disorders, Genetic Disorders, Metabolic Disorders and Ophthalmology which include indications Alzheimer's Disease, Solid Tumor, Non-Small Cell Lung Cancer, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Neuroendocrine Tumors, Pancreatic Cancer, Amyotrophic Lateral Sclerosis, Brain Cancer, Central Nervous System (CNS) Tumor, Colorectal Cancer, Fibrosarcoma, Gastrointestinal Stromal Tumor (GIST), Huntington Disease, Metastatic Colorectal Cancer, Multiple Sclerosis, Neuroblastoma, Ovarian Cancer, Parkinson's Disease, Renal Cell Carcinoma, Salivary Gland Cancer, Soft Tissue Sarcoma, Thyroid Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Large Cell Lymphoma (ALCL), Astrocytoma, Biliary Tumor, Bladder Cancer, Carcinoid Tumor, Charcot-Marie-Tooth Disease, Diabetic Retinopathy, Endometrial Cancer, Epilepsy, Epithelial Ovarian Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hearing Disorders, Hepatocellular Carcinoma, Ischemic Optic Neuropathy, Major Depressive Disorder, Melanoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neurology, Non-Rhabdomyosarcoma, Non-Small Cell Lung Carcinoma, Ocular Melanoma, Osteosarcoma, Papillary Thyroid Cancer, Peritoneal Cancer, Pheochromocytoma, Pontine Glioma, Post-Traumatic Stress Disorder (PTSD), Prostate Cancer, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rett Syndrome, Rhabdomyosarcoma, Stroke, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Traumatic Brain Injury, Ureter Cancer, Urethral Cancer, Uterine Cancer and Wilms' Tumor (Nephroblastoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)

- The report reviews BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Overview
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
AstraZeneca Plc
Boehringer Ingelheim GmbH
Chronos Therapeutics Ltd
Daiichi Sankyo Co Ltd
Exelixis Inc
Handok Inc
Ignyta Inc
Loxo Oncology Inc
MimeTech Srl
Otonomy Inc
Plexxikon Inc
Takeda Pharmaceutical Co Ltd
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Drug Profiles
ACD-855 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Agonize TrKB for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-7451 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNN-27 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-6051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larotrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22A4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22B10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OTO-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-7486 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-0131304 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize TrkA and TrkB for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize TRKB for Neurodegenrative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide Agonize TrkA and TrkB Alzheimer's Disease and Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize TrkB for CNS Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Dormant Products
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Discontinued Products
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Jan 16, 2018: Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstrating Significant Overall Survival Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma
Jan 15, 2018: Data To Be Presented On cabozantinib (Cabometyx) At 2018 ASCO Gastrointestinal Symposium
Jan 15, 2018: Diplomat Dispensing Advanced Kidney Treatment, CABOMETYX
Jan 09, 2018: Exelixis to Co-Host Financial Community Briefing to Discuss Data Presented at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Jan 04, 2018: Exelixis Announces Amendment to Clinical Research Protocol for Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
Dec 20, 2017: Bayer announces initiation of rolling submission of new drug application in the U.S. for larotrectinib for the treatment of TRK fusion cancers
Dec 20, 2017: Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers
Dec 19, 2017: Exelixis Announces U.S. FDA Approval of CABOMETYX (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
Dec 07, 2017: Bayer to Highlight New Oncology Research on larotrectinib at ASH 2017
Dec 04, 2017: Updated larotrectinib pediatric clinical trial data demonstrate continued durability of response in TRK fusion cancers
Nov 21, 2017: Exelixis Announces Phase 3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma to be Presented at 2018 Gastrointestinal Cancers Symposium
Oct 19, 2017: AlzeCure to Present Data on NeuroRestore Project at 10th annual Conference on Clinical Trials for Alzheimer's Disease (CTAD)
Oct 18, 2017: Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset
Oct 17, 2017: Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors
Oct 17, 2017: Interim Analysis of Ignytas Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Addex Therapeutics Ltd, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Boehringer Ingelheim GmbH, H1 2018
Pipeline by Chronos Therapeutics Ltd, H1 2018
Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Pipeline by Exelixis Inc, H1 2018
Pipeline by Handok Inc, H1 2018
Pipeline by Ignyta Inc, H1 2018
Pipeline by Loxo Oncology Inc, H1 2018
Pipeline by MimeTech Srl, H1 2018
Pipeline by Otonomy Inc, H1 2018
Pipeline by Plexxikon Inc, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Enzymatic Debridement Market 2018, Forecast to 2023
    Published: 15-Jun-2018        Price: US 4880 Onwards        Pages: 133
    Enzymatic Debridement uses chemical enzymes to assist in wound healing. Enzymes that help slough off the dead tissue are often available as part of a topic ointment; however, the ointment must be carefully applied to only the currently dead tissue - if the enzymes come in contact with healthy tissue, they could cause issues. Scope of the Report: This report focuses on the Enzymatic Debridement in global market, especially in North America, Europe and Asia-Pacific, South Ame......
  • Global Enzymatic Debridement Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Jun-2018        Price: US 3480 Onwards        Pages: 129
    Enzymatic Debridement uses chemical enzymes to assist in wound healing. Enzymes that help slough off the dead tissue are often available as part of a topic ointment; however, the ointment must be carefully applied to only the currently dead tissue - if the enzymes come in contact with healthy tissue, they could cause issues. Scope of the Report: This report focuses on the Enzymatic Debridement in global market, especially in North America, Europe and Asia-Pacific, South Ame......
  • Global Vaccine Market, People Vaccinated, Administered, Immunization, By Disease, By End User, Companies
    Published: 14-Jun-2018        Price: US 1990 Onwards        Pages: 355
    Global Vaccine Market is projected to reach US$ 70 Billion by the year 2024. The vaccine market is likely to witness a significant growth throughout the forecast period due to the growing prevalence of diseases, increasing government and non-government funding for vaccine development & distribution and increasing investments by companies to develop new vaccines. Furthermore, growing demand for preventive vaccines, rising consciousness about vaccination coupled with mounting demand from th......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Celery Seed Extract Solid Market 2018, Forecast to 2023
    Published: 13-Jun-2018        Price: US 4880 Onwards        Pages: 128
    Celery seed solid extract and oil are majorly used for healthcare benefits as anti-spasmodic, nerve stimulant, stimulant and tonic in asthma, rheumatoid arthritis, intestinal antiseptic. The essential oil of celery seed comprise of sesquiterpene alcohols, sedanolide, d-limonene, selinene, and sedanonic anhydride. Celery oil is mostly used for flavoring of food and perfumes. Scope of the Report: This report focuses on the Celery Seed Extract Solid in global market, especial......
  • Global Celery Seed Extract Solid Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 13-Jun-2018        Price: US 3480 Onwards        Pages: 135
    Celery seed solid extract and oil are majorly used for healthcare benefits as anti-spasmodic, nerve stimulant, stimulant and tonic in asthma, rheumatoid arthritis, intestinal antiseptic. The essential oil of celery seed comprise of sesquiterpene alcohols, sedanolide, d-limonene, selinene, and sedanonic anhydride. Celery oil is mostly used for flavoring of food and perfumes. Scope of the Report: This report focuses on the Celery Seed Extract Solid in global market, especial......
  • Active Pharmaceutical Ingredients: Global Markets to 2022
    Published: 12-Jun-2018        Price: US 5500 Onwards        Pages: 164
    Report Scope This report (Active Pharmaceutical Ingredients: Global Markets to 2022) covers an overview of the pharmaceutical industry landscape and active pharmaceutical ingredients (API), along with the current trends and dynamics shaping the API market landscape. API sourcing trends and regulatory guidelines that impact the procurement of API are studied here. The increasing importance of API outsourced manufacturing activities and the impact on the pharmaceutical industry are co......
  • Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H1 2018
    Published: 12-Jun-2018        Price: US 3500 Onwards        Pages: 45
    Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H1 2018 Summary Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules ......
  • Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Pipeline Review, H1 2018
    Published: 12-Jun-2018        Price: US 3500 Onwards        Pages: 39
    Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Pipeline Review, H1 2018 Summary According to the recently published report 'Tryptophan 2,3 Dioxygenase - Pipeline Review, H1 2018'; Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) pipeline Target constitutes close to 12 molecules......
  • Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H1 2018
    Published: 12-Jun-2018        Price: US 3500 Onwards        Pages: 67
    Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H1 2018 Summary Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase ROS is an enzyme that in humans is encoded by the ROS1 gen......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs